Log in

NASDAQ:ROSG - Rosetta Genomics Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range N/A
50-Day Range
$0.43
MA: $0.43
$0.43
52-Week Range N/A
Volume169,599 shs
Average Volume81,512 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ROSG
CUSIPN/A
Phone972-73-222-0700

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive ROSG News and Ratings via Email

Sign-up to receive the latest news and ratings for ROSG and its competitors with MarketBeat's FREE daily newsletter.


(Ad)


If you're happy with stocks yielding you 4% or 5% a year, you don't need this. But if you want to see how we built a portfolio that now pays us a 67% cash on cash return - with no leverage, options, or gimmicks.

Rosetta Genomics (NASDAQ:ROSG) Frequently Asked Questions

What is Rosetta Genomics' stock symbol?

Rosetta Genomics trades on the NASDAQ under the ticker symbol "ROSG."

How were Rosetta Genomics' earnings last quarter?

Rosetta Genomics (NASDAQ:ROSG) posted its quarterly earnings results on Thursday, May, 19th. The medical research company reported ($0.18) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.16) by $0.02. The medical research company earned $2.60 million during the quarter, compared to analysts' expectations of $3.36 million. View Rosetta Genomics' Earnings History.

Has Rosetta Genomics been receiving favorable news coverage?

Media stories about ROSG stock have been trending somewhat negative on Sunday, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Rosetta Genomics earned a media sentiment score of -1.5 on InfoTrie's scale. They also assigned headlines about the medical research company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Rosetta Genomics.

Who are some of Rosetta Genomics' key competitors?

What other stocks do shareholders of Rosetta Genomics own?

Who are Rosetta Genomics' key executives?

Rosetta Genomics' management team includes the folowing people:
  • Mr. Kenneth A. Berlin, Pres & CEO (Age 54)
  • Mr. Ron Kalfus CPA, Chief Financial Officer (Age 44)
  • Mr. Oded Biran Adv., Gen. Counsel and Sec. (Age 39)
  • Dr. Eti Meiri Ph.D., VP of Research (Age 50)
  • Ms. Ana C. Ward Esq., M.S.,M.B.A., Exec. VP of Legal and Corp. Devel.

What is Rosetta Genomics' official website?

The official website for Rosetta Genomics is http://www.rosettagenomics.com/.

How can I contact Rosetta Genomics?

Rosetta Genomics' mailing address is 10 PLAUT STREET SCIENCE PARK, REHOVOT L3, 76706. The medical research company can be reached via phone at 972-73-222-0700 or via email at [email protected]


MarketBeat Community Rating for Rosetta Genomics (NASDAQ ROSG)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  200 (Vote Outperform)
Underperform Votes:  165 (Vote Underperform)
Total Votes:  365
MarketBeat's community ratings are surveys of what our community members think about Rosetta Genomics and other stocks. Vote "Outperform" if you believe ROSG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ROSG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2020 by MarketBeat.com Staff

Featured Article: What are economic reports?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel